PMID- 18289034
OWN - NLM
STAT- MEDLINE
DCOM- 20080702
LR  - 20191027
IS  - 1871-5273 (Print)
IS  - 1871-5273 (Linking)
VI  - 7
IP  - 1
DP  - 2008 Feb
TI  - Targeting neurotrophin receptors in the central nervous system.
PG  - 71-82
AB  - Neurotrophic factors, and in particular the neurotrophins, restore the function 
      of damaged neurons and prevent apoptosis in adults. The potential therapeutic 
      property of the neurotrophins is however, complicated by the peptidergic 
      structure of these trophic factors, which impairs their penetration into the 
      brain parenchyma, and therefore makes their pharmaco-therapeutic properties 
      difficult to evaluate. In this article we will focus on the neurotrophin 
      Brain-derived neurotrophic factor (BDNF) and its receptors to address various 
      therapeutic strategies that may overcome this problem. We will call this strategy 
      "small molecule approach" because it relies on increasing the function of 
      endogenous neurotrophins by pharmacological compounds that induce synthesis and 
      release of neurotrophins in relevant brain areas or by small synthetic molecules 
      that bind and activate specific neurotrophin receptors. The ability of small 
      molecules to mimic BDNF has a potential therapeutic importance in preventing 
      neuronal damage in several chronic neurodegenerative diseases including 
      Parkinson's Disease, Alzheimer's Disease, and AIDS dementia.
FAU - Mocchetti, Italo
AU  - Mocchetti I
AD  - Department of Neuroscience, Georgetown University Medical Center, Washington DC 
      20057, USA. moccheti@georgetown.edu
FAU - Brown, Milton
AU  - Brown M
LA  - eng
GR  - NS040670/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Gangliosides)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Receptors, Nerve Growth Factor)
SB  - IM
MH  - Animals
MH  - Central Nervous System/*metabolism
MH  - Gangliosides/chemistry/pharmacology
MH  - Humans
MH  - Models, Molecular
MH  - Nerve Growth Factors/*pharmacology/therapeutic use
MH  - Receptors, Nerve Growth Factor/classification/*metabolism
MH  - Signal Transduction/*drug effects/physiology
RF  - 170
EDAT- 2008/02/22 09:00
MHDA- 2008/07/03 09:00
CRDT- 2008/02/22 09:00
PHST- 2008/02/22 09:00 [pubmed]
PHST- 2008/07/03 09:00 [medline]
PHST- 2008/02/22 09:00 [entrez]
AID - 10.2174/187152708783885138 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2008 Feb;7(1):71-82. doi: 
      10.2174/187152708783885138.